Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Adverum Biotechnologies, Inc (AAVL)  
$14.95 0.00 (0.00%) as of 4:30 Mon 3/25


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 435,170,000
Market Cap: 6.51(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.75 - $16.06
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Co.'s primary product candidate, ADVM-022, is a single, in-office intravitreal (IVT) injection gene therapy product. ADVM-022 is being developed for the treatment of patients with wet age-related macular degeneration who are responsive to anti-vascular endothelial growth factor therapy. Co.'s second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy via a single IVT injection.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 230,000 230,000 330,000 410,000
Total Buy Value $310,500 $310,500 $455,990 $523,453
Total People Bought 2 2 3 7
Total Buy Transactions 2 2 3 8
Total Shares Sold 0 0 6,201 140,082
Total Sell Value $0 $0 $9,429 $134,803
Total People Sold 0 0 1 5
Total Sell Transactions 0 0 1 9
End Date 2024-01-25 2023-10-24 2023-04-25 2022-04-25

   
Records found: 266
  Page 1 of 11  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Lupher, Jr. Mark L.   –       •      –    2024-02-07 4 B $1.35 $175,500 D/D 130,000 130,000 0.01 432%     
   Scopa James Paul   –       •      –    2024-02-07 4 B $1.35 $135,000 D/D 100,000 100,000 0.01 432%     
   Seyedkazemi Setareh Chief Development Officer   •       –      –    2023-09-15 4 S $1.52 $9,429 D/D (6,201) 47,674 43%     
   Rubinstein Linda M Chief Financial Officer   •       –      –    2023-06-07 4 B $1.45 $145,490 D/D 100,000 100,000 2.74 -41%     
   Riley Brigit Chief Scientific Officer   •       –      –    2023-03-15 4 S $0.78 $5,705 D/D (7,299) 117,435 -113%     
   Fischer Laurent CEO, President and Director   •       •      –    2023-03-15 4 S $0.78 $32,232 D/D (41,239) 692,141 -113%     
   Soparkar Peter Chief Operating Officer   •       –      –    2023-03-15 4 S $0.78 $10,442 D/D (13,360) 265,891 -113%     
   Fischer Laurent CEO, President and Director   •       •      –    2022-09-19 4 S $1.07 $43,941 D/D (41,082) 727,380 38%     
   Seyedkazemi Setareh Chief Development Officer   •       –      –    2022-09-19 4 S $1.07 $6,480 D/D (6,058) 47,875 38%     
   Riley Brigit Chief Scientific Officer   •       –      –    2022-09-19 4 S $1.07 $7,772 D/D (7,266) 118,734 38%     
   Soparkar Peter See Remarks section   •       –      –    2022-09-19 4 S $1.07 $14,232 D/D (13,305) 273,251 38%     
   Beckman Richard Chief Medical Officer   •       –      –    2022-09-19 4 S $1.07 $4,570 D/D (4,272) 39,061 38%     
   Beckman Richard Chief Medical Officer   •       –      –    2022-09-14 4/A A $0.00 $0 D/D 33,333 43,333     -
   Seyedkazemi Setareh Chief Development Officer   •       –      –    2022-09-14 4 A $0.00 $0 D/D 33,333 53,933     -
   Beckman Richard Chief Medical Officer   •       –      –    2022-09-14 4 A $0.00 $0 D/D 25,000 35,000     -
   Rakow John SVP, Genl Counsel, Acting CFOO   •       –      –    2022-06-03 3 IO $0.00 $0 D/D 0 58,233 -8%     
   Seyedkazemi Setareh Chief Development Officer   •       –      –    2022-05-23 4 B $0.84 $16,800 D/D 20,000 20,600 2.74 21%     
   Beckman Richard Chief Medical Officer   •       –      –    2022-05-17 4 B $0.82 $8,228 D/D 10,000 10,000 2.74 6%     
   Dsouza Rupert Chief Financial Officer   •       –      –    2022-05-17 4 B $0.83 $8,272 D/D 10,000 20,850 2.74 6%     
   Graham Dawn Director   –       •      –    2022-05-16 4 B $0.85 $25,578 D/D 30,000 50,000 2.39 9%     
   Dsouza Rupert Chief Financial Officer   •       –      –    2022-05-13 4 B $0.86 $8,585 D/D 10,000 10,850 2.74 16%     
   Fischer Laurent CEO, President and Director   •       •      –    2022-04-20 4 B $1.11 $27,800 D/D 25,000 762,462 2.81 6%     
   Soparkar Peter See Remarks section   •       –      –    2022-04-19 4 B $1.14 $24,994 D/D 21,925 280,556 2.74     -
   Seyedkazemi Setareh Chief Development OfficerOffic   •       –      –    2022-01-06 3 IO $0.00 $0 D/D 0 600 -51%     
   Fischer Laurent CEO, President and Director   •       •      –    2021-12-09 4 B $1.85 $26,498 D/D 14,323 737,462 2.81 -39%     
  266 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 11
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us